Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: AbbVie | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: AbbVie

Revenues up 9% in the quarter driven by Humira and Imbruvica

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbbVie
3Q Revenues: $7.0 billion (+9%)
3Q Earnings: $1.6 billion (+2%)
YTD Revenues: $20.5 billion (+9%)
YTD Earnings: $5.3 billion (+7%)
Comments: Humira sales were $4.7 billion in the quarter, up 16%. Imbruvica sales were $688 million, up 37%. HCV sales were down 27% to $276 million due to increased competition in the Hep-C market. Lupron sales were $201 million, up 4%. Creon sales were up 15% to $215 million. Synagis sales were up 21% to $116 million. Synthroid sales were $191 million, up 2%. AndroGel sales were down 15% to $147 million. Kaletra sales were down 38% to $85 million.   

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters